So the original links to the drop seem to be dead. I found the original forums where it was posted, but not the original thread. I did find another thread with a release of older data from a few years ago, and a backup link to the drop. Thread located atl https://raidforums.com/Thread-CSV-Pfizer-Medical-Customers-Orders-Leaks File is located at: https://anonfiles.com/31yace9bpb/-rGv_zip Edit: Reading through some emails and the rolling update document from the end of November, the interesting information I've found: (As of November) Regulatory approval is being sought to market and deliver vaccines. Main issue appears to be in mid-Nov was that commercial (aka delivered) products had down to 50% fragmented species of mRNA present. The goal is 70% to ensure the vaccine is potent enough to work. It appears this issue may have been fixed within a few weeks. Further, the rolling update document "Quality rolling review CHMP overview and list of questions" for the COVID-19 mRNA Vaccine BioNTech, 30 November 2020, states on page 21 that "...the potential safety risks associated with truncated RNA isoforms are not addressed." This is in relation to discussing impurities in vaccines. From this section: `Process-related and product-related impurities as well as potential contaminants are described in this section. Five batches were evaluated for impurities, i.e. clinical, initial emergency supply and PPQ batches. It is noted that this section is incomplete and will be updated after PPQ completion. The sole product-related impurity addressed is double-stranded RNA, derived from the in-vitro transcription reaction. Results from the five DS batches demonstrate that the level of double stranded RNA is low, acceptable and consistent. In addition to double stranded RNA, there are more product-related impurities, i.e. truncated RNA, also referred to as fragmented species. Truncated RNA is reflected in the DS specification in terms of RNA integrity. However, the characterisation of BNT162b2 DS is currently not found acceptable in relation to the CQA RNA integrity. Significant differences between batches manufactured by Process 1 and 2 are observed for this specific attribute. Even though two methods, namely agarose gel electrophoresis and capillary gel electrophoresis, have been applied to determine RNA integrity of BNT162b2 DS, no characterisation data on RNA integrity and truncated forms is presented and the potential safety risks associated with truncated RNA isoforms are not addressed. This is especially important considering that the current DS and DP acceptance criteria allows for up to 50% fragmented species. Therefore, the dossier should be updated with additional characterisation data and discussion on mRNA integrity, this is considered a major objection.` In simpler terms, the RNA is doing things in the vaccine vials, to include: 1.Spontaneous combination into double-stranded RNA 2.Degradation into shorter-strand RNA molecules From this November document, it appears safety concerns for number 2 above have not been sufficiently investigated (again, as of November). The lack of safety information for these truncated RNA fragments constitutes a major objection.